JP4659358B2 - 経口インスリン療法 - Google Patents

経口インスリン療法 Download PDF

Info

Publication number
JP4659358B2
JP4659358B2 JP2003557529A JP2003557529A JP4659358B2 JP 4659358 B2 JP4659358 B2 JP 4659358B2 JP 2003557529 A JP2003557529 A JP 2003557529A JP 2003557529 A JP2003557529 A JP 2003557529A JP 4659358 B2 JP4659358 B2 JP 4659358B2
Authority
JP
Japan
Prior art keywords
insulin
oral
cnab
concentration
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003557529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525308A (ja
JP2005525308A5 (https=
Inventor
エハド アービット
リチャット アッバース
マイケル ゴールドバーグ
ティー クーパー ウッズ
スティーヴン ディン
ヴィヴィアン ウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Publication of JP2005525308A publication Critical patent/JP2005525308A/ja
Publication of JP2005525308A5 publication Critical patent/JP2005525308A5/ja
Application granted granted Critical
Publication of JP4659358B2 publication Critical patent/JP4659358B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003557529A 2002-01-07 2003-01-07 経口インスリン療法 Expired - Fee Related JP4659358B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34674602P 2002-01-07 2002-01-07
US34731202P 2002-01-09 2002-01-09
US36861702P 2002-03-29 2002-03-29
US37497902P 2002-04-23 2002-04-23
US38936402P 2002-06-17 2002-06-17
US10/237,138 US20030198666A1 (en) 2002-01-07 2002-09-06 Oral insulin therapy
PCT/US2003/000337 WO2003057170A2 (en) 2002-01-07 2003-01-07 Oral insulin therapy

Publications (3)

Publication Number Publication Date
JP2005525308A JP2005525308A (ja) 2005-08-25
JP2005525308A5 JP2005525308A5 (https=) 2006-03-02
JP4659358B2 true JP4659358B2 (ja) 2011-03-30

Family

ID=27559275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003557529A Expired - Fee Related JP4659358B2 (ja) 2002-01-07 2003-01-07 経口インスリン療法

Country Status (6)

Country Link
US (2) US20030198666A1 (https=)
EP (1) EP1469812B1 (https=)
JP (1) JP4659358B2 (https=)
AU (1) AU2003226436B2 (https=)
CA (1) CA2471769C (https=)
WO (1) WO2003057170A2 (https=)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
CA2511530C (en) * 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
WO2004080401A2 (en) * 2003-03-06 2004-09-23 Emisphere Technologies, Inc. Oral insulin therapies and protocol
JP2006519881A (ja) * 2003-03-06 2006-08-31 エミスフィアー テクノロジーズ インコーポレイテッド 経口インスリン治療及びプロトコール
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20050049152A1 (en) * 2003-08-29 2005-03-03 Wark Robert E. Wakeboard binding lubricant and method of using same
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
CN1968704B (zh) 2004-05-19 2010-12-08 爱密斯菲尔科技公司 局部用色甘酸制剂
AU2005244985B2 (en) 2004-05-19 2011-09-01 Emisphere Technologies, Inc. Acyclovir formulations
EP1750755A1 (en) * 2004-06-02 2007-02-14 Technion Research And Development Foundation, Ltd. Methods and formulations for increasing intestinal function
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
CN101014360A (zh) 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US7318920B2 (en) * 2004-09-27 2008-01-15 Ez-Med Company Low water activity nutritional product having beneficial microbial and high oil content
WO2006072070A2 (en) 2004-12-29 2006-07-06 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
EP1933862B1 (en) * 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US9364215B2 (en) * 2006-01-26 2016-06-14 Covidien Lp Medical device package
US20090209031A1 (en) * 2006-01-26 2009-08-20 Tyco Healthcare Group Lp Medical device package
US20070170080A1 (en) * 2006-01-26 2007-07-26 Joshua Stopek Medical device package
CN103736165B (zh) * 2006-02-09 2017-05-10 德卡产品有限公司 流体分配器件、流体流的测量方法和系统及流体输送系统
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070250375A1 (en) * 2006-02-24 2007-10-25 Mcclellan William Dynamic Capture Rate Performance Metric
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US8426466B2 (en) 2006-05-22 2013-04-23 Nexus Pharma, Inc. Compositions and methods for enhancing active agent absorption
JP5475443B2 (ja) 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
CA2604433A1 (en) * 2006-10-06 2008-04-06 Tyco Healthcare Group Lp Medical device package including self-puncturable port
US20080171972A1 (en) * 2006-10-06 2008-07-17 Stopek Joshua B Medical device package
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2008144690A2 (en) * 2007-05-21 2008-11-27 Nexus Pharma, Inc. Compositions and methods for enhancing active agent absorption
US20080317858A1 (en) * 2007-06-25 2008-12-25 Jinling Chen Formulations of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009094846A1 (en) * 2007-12-28 2009-08-06 Shanghai Institute Of Pharmaceutical Industry Insulin nasal powder inhalation
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20110046079A1 (en) * 2008-01-16 2011-02-24 Mullin James M Use of Proton Pump Inhibitors as Drug Delivery Adjuvants
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
CN105903005A (zh) 2008-05-05 2016-08-31 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
UA103329C2 (ru) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
RU2494755C2 (ru) * 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010090876A2 (en) 2009-01-21 2010-08-12 University Of Florida Research Foundation, Inc. Satiation peptide administration
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2767342C (en) 2009-07-09 2018-05-01 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
EP2461803B1 (en) 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2786476A1 (en) * 2010-01-14 2011-07-21 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
AU2011265294B2 (en) 2010-06-10 2015-01-22 Aquestive Therapeutics, Inc. Nanoparticle film delivery systems
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
EP2790704B1 (en) * 2011-12-12 2019-04-03 Melior Pharmaceuticals I, Inc. Treatment of type i diabetes
US10398762B2 (en) 2012-01-03 2019-09-03 Oramed Ltd. Methods and compositions for treating diabetes
JP6567827B2 (ja) 2012-02-01 2019-08-28 オラムド エルティーディー． プロテアーゼ阻害剤を含有する組成物、該組成物を含む組成物、および、該組成物を製造および使用する方法
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN113713090B (zh) 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
WO2017101867A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
TWI725092B (zh) * 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
IL264880B2 (en) 2016-08-17 2024-09-01 Entera Bio Ltd Preparations for oral administration of active substances
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
JP2021512051A (ja) 2018-01-23 2021-05-13 ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドｙｙ薬学的調剤物、組成物、および方法
CN112512534A (zh) * 2018-05-14 2021-03-16 艾伊拉米治疗有限公司 用于回溶为高浓度液态溶液的胰岛素制剂
US10835505B2 (en) * 2018-06-11 2020-11-17 Aardvark Therapeutics, Inc. Oral pharmaceutical formulation for weight loss, diabetes and related disorders
AU2020354634A1 (en) * 2019-09-25 2022-04-14 Aardvark Therapeutics Inc. Oral pharmaceutical immediate release composition and method of treatment for weight loss
CN111925298B (zh) * 2020-09-02 2023-05-30 无锡紫杉药业有限公司 一种4-cnab及其制备方法
CN113929762B (zh) * 2021-12-16 2022-04-26 清华大学 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用
US20250201377A1 (en) * 2022-03-18 2025-06-19 Mannkind Corporation Optimization of dosing and prescribing of medication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
RU2066551C1 (ru) 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5780243A (en) * 1996-06-28 1998-07-14 Thaco Research, Ltd. Methods for the quantitative analysis of organic compounds
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6399090B1 (en) * 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
JP4763957B2 (ja) * 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
JP2004521857A (ja) * 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
NZ524138A (en) 2000-09-06 2004-12-24 Emisphere Tech Inc Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
US20020147135A1 (en) 2000-12-21 2002-10-10 Oliver Schnell Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7137951B2 (en) 2002-10-23 2006-11-21 Joseph Pilarski Method of food and insulin dose management for a diabetic subject

Also Published As

Publication number Publication date
CA2471769A1 (en) 2003-07-17
WO2003057170A8 (en) 2004-01-15
US20030198666A1 (en) 2003-10-23
AU2003226436A1 (en) 2003-07-24
US7429564B2 (en) 2008-09-30
EP1469812A4 (en) 2010-09-29
CA2471769C (en) 2011-03-22
EP1469812B1 (en) 2014-06-25
JP2005525308A (ja) 2005-08-25
AU2003226436B2 (en) 2008-08-28
WO2003057170A3 (en) 2003-12-04
EP1469812A2 (en) 2004-10-27
US20060234913A1 (en) 2006-10-19
WO2003057170A2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
JP4659358B2 (ja) 経口インスリン療法
JP5658619B2 (ja) 経口インスリン治療及びプロトコール
US8324156B2 (en) Oral insulin therapies and protocol
US20180161400A1 (en) Antidiabetic oral insulin biguanide combination
JP5452843B2 (ja) 夜間の経口インスリン治療
JP2006519881A (ja) 経口インスリン治療及びプロトコール
ZA200505426B (en) Night-time oral insulin therapy
HK1085133B (en) Night-time oral insulin therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101220

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101227

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4659358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees